Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9617917 | 0.84 | — | — | |
| SCHEMBL10308328 | 0.83 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1ECE1EPHX1 | |
| SCHEMBL13710824 | 0.83 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1ECE1EPHX1 | |
| SCHEMBL3322985 | 0.79 | GRIK1 (0.35) | SLC1A3SLC1A2SLC1A1ECE1EPHX1 | |
| SCHEMBL4347972 | 0.78 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27849374 | 0.78 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4351614 | 0.78 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9978423 | 0.76 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1ECE1 | |
| SCHEMBL9978421 | 0.76 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1ECE1 | |
| SCHEMBL9978422 | 0.76 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | KCNQ2, KCNQ1, KCNJ2 | SLC1A3 1032/4885SLC1A2 490/4885SLC1A1 636/4885 |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | KCNQ2, KCNQ1, KCNJ2 | SLC1A3 1032/4885SLC1A2 490/4885SLC1A1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.